Health · 3 views
Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder
(MedPage Today) -- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II…
Summary
(MedPage Today) -- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Combination therapy overcomes treatment resistance in breast cancer modelsContinue reading
- Sadiq Khan joins Labour figures urging PM not to water down electric vehicle targets – UK politics liveContinue reading
- Novel Sjogren's Drug Passes First Phase III TestContinue reading
- New atlas traces how key human brain cells develop before and after birthContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow